[5-FU: At last!]

Bull Cancer. 2019 Mar;106(3):173-174. doi: 10.1016/j.bulcan.2019.02.001.
[Article in French]
No abstract available

Publication types

  • Editorial

MeSH terms

  • Acetates / therapeutic use
  • Antidotes / therapeutic use
  • Antimetabolites, Antineoplastic / adverse effects*
  • Antimetabolites, Antineoplastic / therapeutic use
  • Dihydropyrimidine Dehydrogenase Deficiency / complications*
  • Dihydropyrimidine Dehydrogenase Deficiency / genetics
  • Fluorouracil / adverse effects*
  • Fluorouracil / therapeutic use
  • Humans
  • Neoplasms / drug therapy
  • Practice Guidelines as Topic
  • Pyrimidines / adverse effects
  • Pyrimidines / antagonists & inhibitors
  • Uracil / blood
  • Uridine / analogs & derivatives
  • Uridine / therapeutic use

Substances

  • Acetates
  • Antidotes
  • Antimetabolites, Antineoplastic
  • Pyrimidines
  • uridine triacetate
  • Uracil
  • Fluorouracil
  • Uridine